Similar articles

• Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein.

  Herve F, Gomas E, Duche JC, Tillement JP. Herve F, et al. Br J Clin Pharmacol. 1993 Sep;36(3):241-9. doi: 10.1111/j.1365-2125.1993.tb04224.x. Br J Clin Pharmacol. 1993. PMID: 9114911 Free PMC article.
• Comparison of drug binding capacities of two AAG peptidic variants of human origin.

  Bree F, Eap CB, Baumann P, Duche JC, Tillement JP. Bree F, et al. Prog Clin Biol Res. 1989;300:399-403. Prog Clin Biol Res. 1989. PMID: 2780636 No abstract available.
• Contribution of the variants of alpha 1-acid glycoprotein to its binding of drugs.

  Baumann P, Eap CB. Baumann P, et al. Prog Clin Biol Res. 1989;300:379-97. Prog Clin Biol Res. 1989. PMID: 2674972 Review. No abstract available.
• Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.

  Morse DS, Abernethy DR, Greenblatt DJ. Morse DS, et al. Int J Clin Pharmacol Ther Toxicol. 1985 Oct;23(10):535-9. Int J Clin Pharmacol Ther Toxicol. 1985. PMID: 3934087
• Drug binding to human alpha-1-acid glycoprotein in health and disease.

  Kremer JM, Wilting J, Janssen LH. Kremer JM, et al. Pharmacol Rev. 1988 Mar;40(1):1-47. Pharmacol Rev. 1988. PMID: 3064105 Review. No abstract available.